Publications and communications of Ingrid Struman

Shaker, B. T., Ismail, A. A., Salih, R., Hadj Kacem, H., Rahmani, M., Struman, I., & Bajou, K. (17 May 2023). The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis. International Journal of Molecular Sciences, 24 (10), 8877. doi:10.3390/ijms24108877

Guiot, J., Henket, M., Remacle, C., Cambier, M., Struman, I., Winandy, M.-L., Moermans, C., Louis, E., Malaise, M., Ribbens, C., Louis, R., & Njock, M.-S. (15 April 2023). Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis. Respiratory Research, 24 (1), 112. doi:10.1186/s12931-023-02413-6

Cambier, M., Muller, F., Henket, M., Remacle, C., Guiot, J., & Struman, I. (04 September 2022). Extracellular vesicles (EVs) as diagnostic tools in the phenotypic determination of lung tumors [Paper presentation]. ERS International Congress 2022, Barcelone, Spain. doi:10.1183/13993003.congress-2022.1370

NJOCK, M.-S.* , O'Grady, T.* , Nivelles, O., Lion, M., Jacques, S., Cambier, M., Herkenne, S., Muller, F., Christian, A., REMACLE, C., GUIOT, J., Rahmouni, S., Dequiedt, F.* , & Struman, I.*. (June 2022). Endothelial extracellular vesicles promote tumour growth by tumour-associated macrophage reprogramming. Journal of Extracellular Vesicles, 11 (6), 12228. doi:10.1002/jev2.12228
* These authors have contributed equally to this work.

O'Grady, T.* , NJOCK, M.-S.* , Lion, M., Bruyr, J., Mariavelle, E., Galvan, B., Boeckx, A., Struman, I.* , & Dequiedt, F.*. (24 March 2022). Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels. BMC Biology, 20 (1), 72. doi:10.1186/s12915-022-01277-4
* These authors have contributed equally to this work.

Zamberlan, M.* , Boeckx, A.* , Muller, F., Vinelli, F., Ek, O., Vianello, C., Coart, E., Shibata, K., Christian, A., Grespi, F., Giacomello, M., Struman, I., Scorrano, L.* , & Herkenne, S.*. (12 March 2022). Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. Journal of Experimental and Clinical Cancer Research, 41 (1), 95. doi:10.1186/s13046-022-02304-6
* These authors have contributed equally to this work.

Bhardwaj, A., Josse, C., VAN DAELE, D., Poulet, C., Chavez, M., Struman, I., & Van Steen, K. (2022). Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual-and group-level transcriptome network analyses. Scientific Reports, 12 (11027). doi:10.1038/s41598-022-14592-1

Cambier, M., Henket, M., Frix, A.-N., Gofflot, S., THYS, M., Tomasetti, S., Peired, A., Struman, I., Rousseau, A.-F., Misset, B., Darcis, G., Moutschen, M., Louis, R., Njock, M.-S., Cavalier, E., & Guiot, J. (2022). Increased KL-6 levels in moderate to severe COVID-19 infection. PLoS ONE, 17 (11), 0273107. doi:10.1371/journal.pone.0273107

Fontaine, M., Herkenne, S., Ek, O., Paquot, A., Boeckx, A., Paques, C., Nivelles, O., Thiry, M., & Struman, I. (2022). Extracellular Vesicles Mediate Communication between Endothelial and Vascular Smooth Muscle Cells. International Journal of Molecular Sciences, 23 (1). doi:10.3390/ijms23010331

Guiot, J., HENKET, M., NJOCK, M.-S., MOERMANS, C., Struman, I., Corhay, J.-L., & Louis, R. (2021). La fibrose pulmonaire : des biomarqueurs à de nouveaux horizons thérapeutiques. Revue Médicale de Liège, 76 (3), 166-172.

Parzibut, G., Henket, M., Moermans, C., Struman, I., Louis, E., Malaise, M., Louis, R., Misset, B., NJOCK, M.-S.* , & Guiot, J.*. (2021). A Blood Exosomal miRNA Signature in Acute Respiratory Distress Syndrome. Frontiers in Molecular Biosciences, 8, 640042. doi:10.3389/fmolb.2021.640042
* These authors have contributed equally to this work.

Roblain, Q., Louis, T., Yip, C., Baudin, L., Struman, I., Caolo, V., LAMBERT, V., Lecomte, J.* , Noël, A.* , & Heymans, S.*. (2021). Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging, 13. doi:10.18632/aging.203035
* These authors have contributed equally to this work.

GUIOT, J., Cambier, M., Boeckx, A., HENKET, M., Nivelles, O., GESTER, F., LOUIS, E., MALAISE, M., Dequiedt, F., LOUIS, R., Struman, I.* , & NJOCK, M.-S.*. (05 August 2020). Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax, 75 (10), 870-881. doi:10.1136/thoraxjnl-2019-214077
* These authors have contributed equally to this work.

Pérez-Boza, J., Boeckx, A., Lion, M., Dequiedt, F., & Struman, I. (2020). hnRNPA2B1 inhibits the exosomal export of miR‑503 in endothelial cells. Cellular and Molecular Life Sciences. doi:10.1007/s00018-019-03425-6

Francart, M.-E.* , Vanwynsberghe, A.* , Lambert, J., Bourcy, M., Genna, A., Ancel, J., Perez-Boza, J., Noël, A., Birembaut, P., Struman, I., Polette, M., & Gilles, C. (2020). Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis. Oncogene, 18, 3680-3692. doi:10.1038/s41388-020-1244-1
* These authors have contributed equally to this work.

Boeckx, A., Gourzonès, C., & Struman, I. (06 September 2019). The exosomal microRNA miR-503: a key modulator of resistance to chemotherapy in breast cancer cells [Poster presentation]. EDT-CANCEROLOGY ANNUAL MEETING 2019 RECENT BREAKTHROUGHS IN ANTICANCER DRUG RESISTANCE.

BONHOMME, O., ANDRE, B., GESTER, F., DE SENY, D., MOERMANS, C., Struman, I., Louis, R., MALAISE, M., & GUIOT, J. (2019). Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford, England). doi:10.1093/rheumatology/kez230

GUIOT, J., Struman, I., Louis, E., Louis, R., Malaise, M., & Njock, M.-S. (2019). Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets. Journal of Clinical Medicine, 8 (9). doi:10.3390/jcm8091345

Boeckx, A., Pérez-boza, J., & Struman, I. (14 September 2018). Underlying the exosomal export of a specific microRNA, miR-503, and its implication in resistance to chemotherapy [Poster presentation]. BESEV (Belgian Society for Extracellular Vesicles) First Annual meeting, Gand, Belgium.

Boeckx, A., Pérez-Boza, J., & Struman, I. (13 September 2018). Underlying the exosomal export of the microRNA, miR-503, and its implication in the resistance to chemotherapy [Poster presentation]. Joint meeting GIGA-Cancer Day 2018/ EDT-Cancerology, Liège, Belgium.

Dederen, S., Gourzonès, C., & Struman, I. (13 September 2018). Cell communication via microRNA exchange between endothelial and tumour cells during anti-cancer neoadjuvant therapy [Poster presentation]. JOINT MEETING GIGA-CANCER DAY 2018/EDT-CANCEROLOGY.

Njock, M.-S., O'Grady, T., Nivelles, O., Dequiedt, F., & Struman, I. (13 September 2018). Tumor microenvironment affects the composition of endothelial-derived exosomes: impact in tumor progression [Paper presentation]. GIGA-CANCER DAY, Liège, Belgium.

Pollenus, T., & Struman, I. (June 2018). Study of the crosstalk between VEGF and BMP9 pathways: implications in HHT [Poster presentation]. International Vascular Biology Meeting 2018 (IVBM2018), Helsinki, Finland.

Dederen, S., & Struman, I. (03 May 2018). Cell communication via microRNA exchange between endothelial and tumour cells during anti-cancer neoadjuvant therapy [Poster presentation]. ISEV2018.

Njock, M.-S., GUIOT, J., HENKET, M., Nivelles, O., LOUIS, R., & Struman, I. (May 2018). Sputum exosomes - promising biomarkers for idiopathic pulmonary fibrosis [Poster presentation]. International Society for Extracellular Vesicles, Barcelone, Spain. doi:10.1080/20013078.2018.1461450

O'Grady, T., Njock, M.-S., Lion, M., Struman, I., & Dequiedt, F. (May 2018). Integrating long and short sequencing data for a global overview of the endothelial extracellular vesicle RNA landscape [Poster presentation]. International Society for Extracellular Vesicles, Barcelone, Spain.

Durré, T., Morfoisse, F., ERPICUM, C., Ebroin, M., Blacher, S., García Caballero, M., Deroanne, C., Louis, T., BALSAT, C., Van De Velde, M., Kaijalainen, S., Kridelka, F., Engelholm, L., Struman, I., Alitalo, K., Behrendt, N., Paupert, J., & Noël, A. (2018). uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis. Nature Communications, 9 (1), 5178. doi:10.1038/s41467-018-07514-1

Njock, M.-S., GUIOT, J., HENKET, M., Nivelles, O., Thiry, M., Dequiedt, F., Corhay, J.-L., Louis, R., & Struman, I. (2018). Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax. doi:10.1136/thoraxjnl-2018-211897

Pérez Boza, J., Lion, M., & Struman, I. (2018). Exploring the RNA landscape of endothelial exosomes. RNA. doi:10.1261/rna.064352.117

GUIOT, J., Struman, I., CHAVEZ, V., HENKET, M., Herzog, M., Scoubeau, K., Hardat, N., Bondue, B., Corhay, J.-L., MOERMANS, C., & Louis, R. (15 August 2017). Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clinical Epigenetics, 9, 84. doi:10.1186/s13148-017-0383-x

Njock, M.-S., O'Grady, T., Dequiedt, F., & Struman, I. (2017). Tumour microenvironment affects the composition of endothelial cell-derived extracellular vesicles: impact in tumour progression. Journal of Extracellular Vesicles. doi:10.1080/20013078.2017.1310414

Njock, M.-S., O'Grady, T., Nivelles, O., Dequiedt, F., & Struman, I. (2017). Tumor microenvironment affects the composition of endothelial-derived extracellular vesicles: Impact in tumor progression [Poster presentation]. International Society for Extracellular Vesicles Annual Meeting.

Blomme, A., Fahmy, K., Peulen, O., Costanza, B., Fontaine, M., Struman, I., Baiwir, D., De Pauw, E., Thiry, M., Bellahcene, A., Castronovo, V.* , & Turtoi, A.*. (2016). Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes. Oncotarget. doi:10.18632/oncotarget.13276
* These authors have contributed equally to this work.

Fontaine, M., Paquot, A., Paques, C., & Struman, I. (25 January 2016). Implication of miR-539 and miR-582 in the angiogenesis and the communication between endothelial cells and vascular smooth muscle cells [Poster presentation]. GIGA Day 2016.

Pollenus, T., Paques, C., & Struman, I. (25 January 2016). Study of the crosstalk between the VEGF and the BMP9 pathways and their implication in Hereditary Hemorrhagic Telengiectasia [Poster presentation]. GIGA-DAY 2016.

Rambout, X., Detiffe, C., Bruyr, J., Mariavelle, E., Cherkaoui, M., Brohee, S., Demoitie, P., Lebrun, M., Soin, R., Lesage, B., Guedri, K., Beullens, M., Bollen, M., Farazi, T. A., Kettmann, R., Struman, I., Hill, D. E., Vidal, M., Kruys, V., ... Dequiedt, F. (2016). The transcription factor ERG recruits CCR4-NOT to control mRNA decay and mitotic progression. Nature Structural and Molecular Biology. doi:10.1038/nsmb.3243

Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786
* These authors have contributed equally to this work.

Fontaine, M., Paques, C., & Struman, I. (24 September 2015). Implication of miRNAs in the communication between endothelial cells and vascular muscle cells [Poster presentation]. 6ème congrès de la Société Française d'Angiogenèse.

Fontaine, M., Paques, C., & Struman, I. (11 September 2015). Implication of miRNAs in the communication between endothelial cells and vascular muscle cells [Poster presentation]. EDT-Cancérologie.

Fontaine, M., Bovy, N., & Struman, I. (13 May 2015). Implication of miRNAs in the communication between endothelial cells and vascular muscle cells [Poster presentation]. GIGA-Cancer Day 2015.

Pollenus, T., Paques, C., & Struman, I. (May 2015). Study of the crosstalk between the VEGF and the BMP9 pathways and their implication in Hereditary Hemorrhagic Telengiectasia [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Fontaine, M., Bovy, N., & Struman, I. (27 January 2015). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. GIGA Day 2015.

Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520

Herkenne, S., Paques, C., Nivelles, O., Lion, M., BAJOU, K., Pollenus, T., Fontaine, M., Carmeliet, P., Martial, J., Nguyen, N.-Q.-N., & Struman, I. (2015). The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Science Signaling, 8 (403), 117. doi:10.1126/scisignal.aaa2403

Pollenus, T., Paques, C., & Struman, I. (January 2015). Crosstalk between the VEGF and the TGF-beta pathway and their implication in HHT [Poster presentation]. GIGA-DAY 2015, Liège, Belgium.

Shiva Shankar, T. V., Sulka, B., Hubert, P., Hubaux, R., Delvenne, P., Pendeville-Samain, H., Boittiaux, I., Lambert, D. M., Wouters, J., Maillard, C., Blacher, S., Noël, A., Struman, I., & Willems, L. (2015). N-Hydroxy-6-(5-Nitro- Naphtalimide)-Hexanamide Inhibits Lysine Deacetylation, Mitigates Angiogenesis and Reduces Tumor Growth. Journal of Cancer Sciences, 2 (2), 0-11.

FRERES, P., JOSSE, C., Bovy, N., Boukerroucha, M., Struman, I., BOURS, V., & JERUSALEM, G. (2014). Neoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression. Journal of Cellular Physiology. doi:10.1002/jcp.24730

Fontaine, M., Bovy, N. (Other coll.), & Struman, I. (Other coll.). (19 May 2014). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. GIGA-Cancer Day 2014, Liege, Belgium.

Paques, C., Herkenne, S., Pollenus, T., & Struman, I. (May 2014). Growth Factors-Induced Angiogenesis Requires uPAR on Endothelial Cells [Poster presentation]. Giga Cancer Day, Liège, Belgium.

Fontaine, M., Bovy, N. (Other coll.), & Struman, I. (Other coll.). (01 February 2014). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. Keystone Symposia - RNA Silencing, Seattle, United States.

Fontaine, M., Bovy, N. (Other coll.), & Struman, I. (Other coll.). (27 January 2014). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. GIGA Day 2014, Liege, Belgium.

Bajou, K.* , Herkenne, S.* , Thijssen, V. L., D'Amico, S., Nguyen, N.-Q.-N., Bouche, A., Tabruyn, S., Srahna, M., Carabin, J.-Y., Nivelles, O., Paques, C., Cornelissen, Y., Lion, M., Noël, A., Gils, A., Vinckier, S., Declerck, P. J., Griffioen, A. W., Dewerchin, M., ... Struman, I. (2014). PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine, (7), 741. doi:10.1038/nm.3552
* These authors have contributed equally to this work.

Valencia, K., Luis-Ravelo, D., Bovy, N., Anton, I., Martinez-Canarias, S., Zandueta, C., Ormazabal, C., Struman, I., Tabruyn, S., Rebmann, V., De Las Rivas, J., Guruceaga, E., Bandres, E., & Lecanda, F. (2014). miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Molecular Oncology, 8 (3), 689-703. doi:10.1016/j.molonc.2014.01.012

Fontaine, M., Halkein, J. (Other coll.), Tabruyn, S. (Other coll.), & Struman, I. (Other coll.). (17 May 2013). Endothelium-specific expression of the microRNA miR-146a by using the RCAS system [Poster presentation]. GIGA-Cancer Day 2013, Liège, Belgium.

Erpicum, C., Detry, B., Paupert, J., Maertens, L., Blacher, S., Maillard, C., Thiry, M., Orménèse, S., Struman, I., Behrendt, N., & Noël, A. (28 January 2013). Lymphangiogenesis and extracellular matrix remodeling [Paper presentation]. GIGA-Day, Liège, Belgium.

Haghikia, A., Podewski, E., Libhaber, E., Labidi, S., Fischer, D., Roentgen, P., Tsikas, D., Jordan, J., Lichtinghagen, R., von Kaisenberg, C. S., Struman, I., Bovy, N., Sliwa, K., Bauersachs, J., & Hilfiker-Kleiner, D. (2013). Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Research in Cardiology, 108 (4), 366. doi:10.1007/s00395-013-0366-9

Halkein, J., Tabruyn, S. P., Ricke-Hoch, M., Haghikia, A., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Thiry, M., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation, 123 (5), 2143-54. doi:10.1172/JCI64365

LAMBERT, V., Lecomte, J., Hansen, S., Blacher, S., Alvarez Gonzalez, M.-L., Struman, I., Sounni, N. E., Rozet, E., De Tullio, P., Foidart, J.-M., Rakic, J.-M., & Noël, A. (2013). Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nature Protocols, 8 (11), 2197-2211. doi:10.1038/nprot.2013.135

Paques, C., Herkenne, S., & Struman, I. (2013). Tumor-Induced Angiogenesis Requires uPAR on Endothelial Cells [Poster presentation]. Giga Cancer Day.

Tabruyn, S. P., Hansen, S., Ojeda-Fernandez, M.-L., Bovy, N., Zarrabeitia, R., Recio-Poveda, L., Bernabeu, C., Martial, J., Botella, L.-M., & Struman, I. (2013). MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis. doi:10.1007/s10456-013-9362-9

Detry, B.* , Erpicum, C.* , Paupert, J.* , Blacher, S., Maillard, C., Bruyère, F., Pendeville, H., Remacle, T., LAMBERT, V., Balsat, C., Ormenese, S., Lamaye, F., Janssens, E., Moons, L., CATALDO, D., Kridelka, F., Carmeliet, P., Thiry, M., Foidart, J.-M., ... Noël, A. (24 May 2012). Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood, 119 (21), 5048-56. doi:10.1182/blood-2011-12-400267
* These authors have contributed equally to this work.

Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (19 May 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (19 May 2012). MicroRNA-146a, a downstream effector of 16K prolactin, is a therapeutic target and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Herkenne, S., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (19 May 2012). Implication of the PAI-1/uPA/uPAR signalosome in the antiangiogenic action of 16K prolactin [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (April 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. Biomedica, Liège, Belgium.

Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (April 2012). MicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. Biomedica, Liège, Belgium.

Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (April 2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K prolactin [Poster presentation]. Biomedica, Liège, Belgium.

D'Amico, S., Martial, J., & Struman, I. (2012). A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of Plasminogen Activator Inhibitor Type-1. FEBS Letters, 586, 686-692. doi:10.1016/j.febslet.2012.02.013

Halkein, J., Tabruyn, S., Haghikia, A., Castermans, K., Malvaux, L., Lambert, V., Labidi, S., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (January 2012). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone symposia on Angiogenesis advances in basic sciences and therapeutic applications, Snowbird Resort, Snowbird, Utah, United States.

Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K hPRL [Poster presentation]. Keystone symposia on Angiogenesis: Advances in Basic Science and Therapeutic Applications, Snowbird, United States - Utah.

Hilfiker-Kleiner, D., Struman, I., Hoch, M., Podewski, E., & Sliwa, K. (2012). 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Current Heart Failure Reports, 9 (3), 174-82. doi:10.1007/s11897-012-0095-7

Soares, A. R., Reverendo, M., Pereira, P. M., Nivelles, O., Pendeville, H., Bezerra, A. R., Moura, G. R., Struman, I., & Santos, M. A. S. (2012). Dre-miR-2188 Targets Nrp2a and Mediates Proper Intersegmental Vessel Development in Zebrafish Embryos. PLoS ONE, 7 (6), 39417. doi:10.1371/journal.pone.0039417

Struman, I., Halkein, J., Tabruyn, S., Haghiskia, A., Hoch, M., Nguyen, N.-Q.-N., Malvaux, L., sliwa, K., Noël, A., Martial, J., & Hilfiker-kleiner, D. (2012). MicroRNA-146a, a downstream effector of 16kDa prolactin, impairs the endothelium-cardiomyocyte cross-talk in peripartum cardiomyopathy. In FASEB meeting:the Growth Hormone/Prolactin Family in Biology and Disease.

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318

Struman, I., Martial, J., Bajou, K., & D'Amico, S. (25 August 2011). A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) – placental lactogen (PL)-family protein.

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (May 2011). The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation [Poster presentation]. 4th International Meeting on Angiogenesis, Amsterdam, Netherlands.

Paupert, J., Pendeville, H., Detry, B., Erpicum, C., Maillard, C., Struman, I., Foidart, J.-M., & Noël, A. (May 2011). Involvement of z-MMP-2 in Zebrafish lymphangiogenesis [Poster presentation]. Giga Cancer Day, Liège, Belgium.

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (March 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands.

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (March 2011). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands.

Halkein, J., Bovy, N., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a: an angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Keystone Symposia : MicroRNAs and Non-Coding RNAs and Cancer, Banff, Alberta, Canada.

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone Symposia : MicroRNAs and Human Disease, Banff, Alberta, Canada.

Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Colige, A., Rakic, J.-M., Noël, A., Martial, J., & Struman, I. (February 2011). microRNA-21 Exhibits Anti-Angiogenic Function by Targeting RhoB Expression in Endothelial Cells [Poster presentation]. Keystone Symposia : MicroRNAs and Non-Coding RNAs and Cancer, Banff, Alberta, Canada.

Bajou, K., Herkenne, S., Thijssen, V. L., D'Amico, S., Srahna, M., Carabin, J.-Y., Gils, A., Declerck, P. J., Griffioen, A. W., Martial, J., & Struman, I. (January 2011). PAI-1 mediates antiangiogenic and fibrinolytic actions of prolactin/growth hormone 16-14K fragments [Poster presentation]. Giga-Day Symposia, Liège, Belgium.

COLLIGNON, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., JERUSALEM, G., & BOURS, V. (2011). Aspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques. Revue Médicale de Liège, 66 (5-6), 393-396.

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (January 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Giga-Day Symposia, Liège, Belgium.

Herkenne, S., Bajou, K., D'Amico, S., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2011). Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium.

Kinet, V., Castermans, K., Herkenne, S., Maillard, C., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (2011). The Angiostatic Protein 16K Human Prolactin Significantly Prevents Tumor-Induced Lymphangiogenesis by Affecting Lymphatic Endothelial Cells. Endocrinology. doi:10.1210/en.2011-1081

Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., LAMBERT, V., Alvarez Gonzalez, M.-L., Colige, A., Rakic, J.-M., Noël, A., Martial, J., & Struman, I. (2011). MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. PLoS ONE, 6 (2), 16979. doi:10.1371/journal.pone.0016979

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (October 2010). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Frontiers in Tumor Progression, Madrid, Spain.

Halkein, J., Tabruyn, S., Malvaux, L., Sabatel, C., Martial, J., & Struman, I. (21 May 2010). miR-146a: an anti-angiogenic miRNA regulated by NF-kB [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Herkenne, S., Bajou, K., D'Amico, S., Martial, J., & Struman, I. (21 May 2010). Study of the signalling pathway of 16K PRL and 14K GH for mediate their anti-angiogenic effect [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Kinet, V., Castermans, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (21 May 2010). 16K human prolactin is an anti-lymphangiogenic factor in vitro and in vivo [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Malvaux, L., Pendeville, H., Sabatel, C., Lambert, V., Nivelles, O., Martial, J., & Struman, I. (21 May 2010). Involvement of miR-125b in in vitro and in vivo angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Martial, J., & Struman, I. (May 2010). Study of the role of miR-21 in the regulation of angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Kinet, V., Castermans, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (March 2010). 16K human prolactin is an anti-lymphangiogenic factor in vitro and in vivo [Poster presentation]. Biomedica, Aachen, Germany.

Malvaux, L., Pendeville, H., Sabatel, C., Lambert, V., Nivelles, O., Martial, J., & Struman, I. (March 2010). Involvement of miR-125b in in vitro and in vivo angiogenesis [Poster presentation]. Biomedica, Aachen, Germany.

Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Martial, J., & Struman, I. (March 2010). Study of the role of miR-21 in the regulation of angiogenesis [Poster presentation]. Biomedica, Aachen, Germany.

Sabatel, C., Cornet, A., Tabruyn, S., Malvaux, L., Castermans, K., Martial, J., & Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9 (1), 231. doi:10.1186/1476-4598-9-231

Sliwa, K., Blauwet, L., Tibazarwa, K., Libhaber, E., Smedema, J.-P., Becker, A., McMurray, J., Yamac, H., Labidi, S., Struman, I., & Hilfiker-Kleiner, D. (2010). Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 121 (13), 1465-73. doi:10.1161/CIRCULATIONAHA.109.901496

Pendeville, H., Nivelles, O., Malvaux, L., Voz, M. L., Martial, J., & Struman, I. (July 2009). Finding miRNAs able to regulate angiogenesis [Poster presentation]. 6ème congrès européen sur le Zebrafish, Amsterdam, Netherlands.

Malvaux, L., Pendeville, H., Sabatel, C., Martial, J., & Struman, I. (29 May 2009). Study of the role of microRNAs in angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Pendeville, H., Nivelles, O., Malvaux, L., Voz, M. L., Martial, J., & Struman, I. (29 May 2009). Finding Mir able to regulate angiogenesis [Poster presentation]. GIGA cancer day, Liège, Belgium.

Sabatel, C., Malvaux, L., Cornet, A., Martial, J., & Struman, I. (29 May 2009). Study of the potential regulation of Sprouty1, an angiogenesis inhibitor, by miR-21 [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Castermans, K., Nguyen, N.-Q.-N., Lecomte, J., Noël, A., Martial, J., & Struman, I. (2009). The contribution of vasculogenesis to tumor neovascularization after angiostatic treatment [Poster presentation]. Giga cancer day, liège, Belgium.

Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Regulation of microRNAs expression by the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium.

Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Involvement of microRNAs in the regulation of angiogenesis by the antiangiogenic factor 16K [Poster presentation]. Biomedica, Liège, Belgium.

Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Bajou, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Big Sky, United States - Montana.

Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Letters, 284 (2), 222-228. doi:10.1016/j.canlet.2009.04.030

Nguyen, N.-Q.-N., Camby, S., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Study of the effect of the antiangiogenic factor 16K hPRL in tumor vessel maturation [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Bozeman, United States - Montana.

Nguyen, N.-Q.-N., Camby, S., Lion, M., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the ability of 16K hPRL to affect tumor vessel maturation [Poster presentation]. Biomedica, liège, Belgium.

Nguyen, N.-Q.-N., Lion, M., Blacher, S., Camby, S., Castermans, K., Noël, A., Martial, J., & Struman, I. (2009). The antiangiogenic factor 16K hPRL affects tumor vessel maturation [Poster presentation]. Giga cancer day, Liège, Belgium.

Tabruyn, S., Memet, S., Ave, P., Verhaeghe, C., Mayo, K. H., Struman, I., Martial, J., & Griffioen, A. W. (2009). NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular Cancer Therapeutics, 8 (9), 2645-54. doi:10.1158/1535-7163.MCT-09-0383

Weiner, R. I., Martial, J., Struman, I., Taylor, R., & Bentzien, F. (17 April 2008). Novel antiangiogenic peptide agents and their therapeutic and diagnostic use.

Sabatel, C., Tabruyn, S., Cornet, A., Martial, J., & Struman, I. (30 March 2008). Study of the role of Sprouty1 in the regulation of angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (14 February 2008). Antiangiogenic peptides.

Pendeville-Samain, H., Winandy, M., Manfroid, I., Nivelles, O., Motte, P., Pasque, V., Peers, B., Struman, I., Martial, J., & Voz, M. (2008). Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. Developmental Biology, 317 (2), 405-16. doi:10.1016/j.ydbio.2008.01.028

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294

Erdmann, S., Ricken, A., Merkwitz, C., Struman, I., Castino, R., Hummitzsch, K., Gaunitz, F., Isidoro, C., Martial, J., & Spanel-Borowski, K. (November 2007). The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. American Journal of Physiology - Endocrinology and Metabolism, 293 (5), 1365-E1377. doi:10.1152/ajpendo.00280.2007

Huynh-Thu, V. A., Hiard, S., Geurts, P., Muller, M., Struman, I., Martial, J., & Wehenkel, L. (September 2007). Detection of micro-RNA/gene interactions involved in angiogenesis using machine learning techniques [Poster presentation]. Workshop on Machine Learning in Systems Biology (MLSB07), Evry, France.

Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (02 May 2007). Antiangiogenic peptides.

Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., Bonda, T., Schaefer, A., Sliwa, K., Forster, O., Quint, A., Landmesser, U., Doerries, C., Luchtefeld, M., Poli, V., Schneider, M. D., Balligand, J. L., Desjardins, F., Ansari, A., Struman, I., Nguyen, N.-Q.-N., Zschemisch, N. H., ... Drexler, H. (09 February 2007). A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 128 (3), 589-600. doi:10.1016/j.cell.2006.12.036

Hilfiker-Kleiner, D., Meyer, G. P., Schieffer, E., Goldmann, B., Podewski, E., Struman, I., Fischer, P., & Drexler, H. (2007). Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. Journal of the American College of Cardiology, 50 (24), 2354-5. doi:10.1016/j.jacc.2007.10.006

Kinet, V., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (2007). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia:Host cell response to cancer, Keystone, United States - Colorado.

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Gordon research on angiogenesis, Newport, United States - Rhode Island.

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., FOIDART, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Keystone symposia: Host cell response to cancer, Bozeman, United States - Montana.

Sabatel, C., Tabruyn, S., Cornet, A., Griffioen, A., Martial, J., & Struman, I. (January 2007). Study of the molecular mechanisms involved in the response of tumor and host to the treatment with the antiangiogenic factor 16K prolactin [Poster presentation]. Host cell response to cancer, Keystone, United States.

Tabruyn, S., Sabatel, C., Nguyen, N.-Q.-N., Verhaeghe, Castermans, K., Malvaux, L., Griffioen, A. W., Martial, J., & Struman, I. (2007). The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Molecular Endocrinology, 21 (6), 1422-9. doi:10.1210/me.2007-0021

Cornet, A., Nguyen, N.-Q.-N., Lion, M., Tabruyn, S., Sabatel, C., Kinet, V., Noël, A., Beckers, M.-C., Struman, I., & Martial, J. (May 2006). Molecular profiling of 16K PRL treated tumours by an antibody-array approach [Poster presentation]. Bioforum, Liège, Belgium.

Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Evaluation of 16K Prolactin to prevent metastatic spread through inhibition of angiogenesis [Poster presentation]. Gordon Research Conference: Prolactin Family, Ventura, United States - California.

Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Adenovirus-mediated gene transfer of 16K prolactin inhibits B16-F10 tumor growth and metastasis [Poster presentation]. Bioforum, Liège, Belgium.

Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103 (39), 14319-14324. doi:10.1073/pnas.0606638103

Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Tilted peptides of PRL/GH family and their potential role in angiogenesis [Poster presentation]. Bioforum, Liège, Belgium.

Tabruyn, S., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (July 2005). The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases. Molecular Endocrinology, 19 (7), 1932-1942. doi:10.1210/me.2004-0515

Ricken, A., Merkwitz, C., Struman, I., Martial, J., & Spanel-Borowski, K. (2005). Evidence for a role of prolactin fragments in corpus luteum function. In The society for the study of reproduction Annual meeeting, Quebec 2005 (pp. 240-241). Madison, United States - Wisconsin: Soc Study Reproduction.

Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J., Kelly, P. A., & Goffin, V. (October 2004). Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Molecular Endocrinology, 18 (10), 2522-2542. doi:10.1210/me.2004-0200

Pan, H., Nguyen, N.-Q.-N., Yoshida, H., Bentzien, F., Shaw, L. C., Rentier-Delrue, F., Martial, J., Weiner, R., Struman, I., & Grant, M. B. (July 2004). Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Investigative Ophthalmology and Visual Science, 45 (7), 2413-2419. doi:10.1167/iovs.03-1001

Tabruyn, S., Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (14 May 2004). Molecular mechanisms involved in apoptosis and cell cycle arrest induced by the antiangiogenic factor 16K hPRL [Poster presentation]. Faseb meeting 2005.

Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2004). The 16 kDa N-terminal fragment of the human prolactin. Design and production of minimal peptides retaining antiangiogenic and antitumoral properties [Poster presentation]. Association belge pour l’étude du cancer, Liège, Belgium.

Tabruyn, S., Sorlet, C. M., Rentier-Delrue, F., Bours, V., Weiner, R. I., Martial, J., & Struman, I. (September 2003). The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappa B. Molecular Endocrinology, 17 (9), 1815-1823. doi:10.1210/me.2003-0132

Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). Design and production of minimal peptides that retain antiangiogenic and antitumoral properties of the 16K N-terminal fragment of the human prolactin [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France.

Tabruyn, S., Sorlet, C., Georges, A., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). 16K hPRL prevents angiogenesis by inducing both apoptosis and cell cycle arrest of endothelial cells [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France.

Bentzien, F., Struman, I., Martini, J. F., Martial, J., & Weiner, R. (2001). Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Research, 61 (19), 7356-62.

Struman, I., Sorlet, Vilour, J., Bentzien, F., Lee, H., Rentier-Delrue, F., Lion, M., Weiner, R. I., & Martial, J. (February 2000). The 16 kDa fragments of the PRL/GH family inhibit angiogenesis whereas the full-length hormones stimulate blood vessel formation [Poster presentation]. Gordon Conference on Prolactin, Ventura, California, United States.

Corbacho, A. M., Nava, G., Eiserich, J. P., Noris, G., Macotela, Y., Struman, I., Martinez De La Escalera, G., Freeman, B. A., & Clapp, C. (2000). Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. Journal of Biological Chemistry, 275 (18), 13183-6. doi:10.1074/jbc.275.18.13183

Martini, J. F., Piot, C., Humeau, L. M., Struman, I., Martial, J., & Weiner, R. I. (2000). The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Molecular Endocrinology, 14 (10), 1536-49. doi:10.1210/mend.14.10.0543

Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R. I., & Martial, J. (10 February 1999). Opposing Actions of Intact and N-Terminal Fragments of the Human Prolactin/Growth Hormone Family Members on Angiogenesis: An Efficient Mechanism for the Regulation of Angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 96 (4), 1246-51. doi:10.1073/pnas.96.4.1246

Lee, H., Struman, I., Clapp, C., Martial, J., & Weiner, R. I. (1998). Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology, 139 (9), 3696-703. doi:10.1210/endo.139.9.6194

Mainfroid, V., Struman, I., Weiner, R. I., & Martial, J. (January 1998). Design and characterization of novel forms of human 16K prolactin, an antiangiogenic factor [Poster presentation]. American association for cancer research, Angiogenesis and Cancer, Orlando, United States.

Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R. I., & Martial, J. (January 1998). Antagonistic regulation by intact and N-terminal fragment of the human Prolactin/Growth Hormone family members : a novel mechanism for regulation of angiogenesis [Poster presentation]. American association for cancer research, Angiogenesis and Cancer, Orlando, United States.

Struman, I., Mainfroid, V., Bentzien, F., Weiner, R. I., Goffin, V., & Martial, J. (September 1997). Opposite actions of human Prolactin and its 16-kDa fragment on Angiogenesis [Poster presentation]. Philippe Laudat Conferences - Biology and Physiopathology of Angiogenesis, Aix les Bains, France.

D'Angelo, G., Struman, I., Martial, J., & Weiner, R. I. (1995). Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America, 92 (14), 6374-8. doi:10.1073/pnas.92.14.6374

Goffin, V., Struman, I., Mainfroid, V., Kinet, S., & Martial, J. (23 December 1994). Evidence for a Second Receptor Binding Site on Human Prolactin. Journal of Biological Chemistry, 269 (51), 32598-606.

Goffin, V., Struman, I., Goormaghtigh, E., & Martial, J. (01 June 1993). The Addition of Nine Residues at the C-Terminus of Human Prolactin Drastically Alters Its Biological Properties. European Journal of Biochemistry, 214 (2), 483-90. doi:10.1111/j.1432-1033.1993.tb17945.x

De Moerlooze, L., Struman, I., Renard, A., & Martial, J. (21 September 1992). Stabilization of T7-Promoter-Based Parhs Expression Vectors Using the Parb Locus. Gene, 119 (1), 91-3. doi:10.1016/0378-1119(92)90070-6